HIV Drug Susceptibility and Resistance Tests — CPB 0316 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0316 governing HIV drug susceptibility and resistance test coverage, effective September 26, 2025. Billing teams need to confirm their documentation matches one of three specific clinical triggers before submitting claims under CPT codes 87900, 87901, 87903, 87904, 87906, or the molecular pathology series 81400–81408.

Quick-Reference Table

Aetna HIV Drug Resistance Test Coverage Criteria and Medical Necessity Requirements 2025

The Aetna HIV drug susceptibility and resistance test coverage policy is tighter than most billing teams assume. Aetna covers these tests — but only when the medical record documents one of three specific clinical situations. Get the documentation wrong, and you're looking at a claim denial on a test that can run several hundred dollars in reimbursement.

Here are the three covered indications under CPB 0316:

Acute HIV infection. Aetna covers resistance testing at the time of new-onset HIV diagnosis. The clinical rationale is sound — drug-resistant strains are transmitted, and knowing resistance patterns up front shapes the initial treatment regimen. Document the acute infection clearly with ICD-10 code B20 or Z21, and your record needs to show this is the baseline assessment.

Suboptimal viral load suppression after starting antiretroviral therapy. If a patient begins antiretroviral therapy (ART) and the viral load doesn't suppress as expected, Aetna considers resistance testing medically necessary. The goal is to identify whether resistance is driving the failure and to help clinicians maximize the number of active drugs in the new regimen. Your documentation should capture the specific viral load trajectory and the treatment history.

Virologic failure during HAART. Patients on highly activated antiretroviral therapy (HAART) who experience virologic failure — meaning a rising plasma HIV RNA concentration despite adequate doses of antiretroviral therapy — qualify for resistance testing. This is the most common billing scenario in active HIV practices. The record must document the failure clearly, with viral load data, and exclude other causes before Aetna will treat resistance testing as medically necessary.

These are not interchangeable. Aetna isn't approving resistance testing on a schedule or as routine monitoring. Each claim needs a direct link to one of these three triggers. If your charge capture or order intake process doesn't capture which trigger applies, fix that now — before September 26, 2025.

Prior authorization requirements for CPB 0316 are not explicitly detailed in the published policy language, but high-dollar molecular pathology claims in the 81400–81408 range frequently trigger utilization management review. Check your Aetna contract and portal for current prior auth requirements for the specific codes your lab bills.

Aetna HIV Resistance Test Exclusions and Non-Covered Indications

Two clear non-coverage rules appear in CPB 0316. Both carry real financial exposure if your team misses them.

Simultaneous phenotypic and genotypic testing. Aetna considers it not medically necessary to run both a phenotypic test (CPT 87903, 87904) and a genotypic test (CPT 87901, 87906) at the same time. The policy treats this as duplicative. If your laboratory bills both on the same date of service for the same patient, Aetna will deny one.

There is a narrow exception. If a patient has virologic failure — specifically, a rising plasma HIV RNA concentration while on adequate antiretroviral therapy, with other causes excluded — and one type of resistance assay shows no drug resistance despite ongoing failure, the alternate assay type may be approved on an exception basis. This requires case-by-case review. Don't assume it will auto-approve. Build a documentation workflow for exception requests that clearly states the first assay type used, the results, and the clinical rationale for ordering the second.

CPT 0219U — not covered. The policy lists 0219U (infectious agent targeted viral next-generation sequence analysis for HIV) as not covered for any indications in CPB 0316. If your laboratory has adopted next-gen sequencing workflows and bills 0219U, those claims will not be reimbursed under this coverage policy. This is a hard exclusion — not a documentation fix, not a prior auth pathway. If 0219U is in your charge master for HIV resistance testing billed to Aetna, remove it or flag it for review before the effective date.

Coverage Indications at a Glance

Aetna HIV Resistance Testing Billing Guidelines and Action Items 2025

This coverage policy rewards practices that document clinical triggers precisely. Here's what your billing team and clinical staff need to do before and after September 26, 2025.

If your practice sees significant HIV volume — or if your lab handles HIV resistance testing on behalf of multiple ordering providers — loop in your compliance officer before September 26, 2025. The dual-assay non-coverage rule and the 0219U exclusion are the two areas most likely to generate systematic denial patterns.

CPT, HCPCS, and ICD-10 Codes for HIV Drug Resistance Testing Under CPB 0316

Covered CPT Codes (When Selection Criteria Are Met)

Not Covered / Experimental Codes

Key ICD-10-CM Diagnosis Codes

A note on ICD-10 pairing: B20 is your primary code for active HIV disease across all three covered indications. Z21 applies to asymptomatic HIV status — most relevant when billing resistance testing at the time of acute diagnosis before disease progression. B97.35 covers HIV-2 specifically. If your patient population includes HIV-2 cases, confirm that the clinical criteria in CPB 0316 apply equally, since most resistance testing policy language — including this one — focuses primarily on HIV-1 strains.